Modalis Therapeutics and its lead program, MDL-101, have been highlighted as an innovative treatment with notable progress by LAMA2 Europe, a European LAMA2-CMD patient organization, and the article was published on the LAMA2 Europe website.

The article refers to preclinical data published by Modalis Therapeutics and states that MDL-101 is a promising innovative treatment in future clinical trials due to its small doses and enhanced safety profile. As a leading company in the development of fundamental therapies for LAMA2-CMD, Modalis will continue to move forward to bring hope to patients suffering from rare genetic disorders for which there are no cure solutions.

MODALIS THERAPEUTICS ADVANCES A NOVEL GENE THERAPY FOR LAMA2-CMD

“Modalis Therapeutics has made significant strides in developing a gene therapy technology aimed at treating LAMA2-congenital muscular dystrophy (LAMA2-CMD)”

About LAMA2 Europe

LAMA2 Europe is a non-profit organization organized and managed by the European LAMA2-CMD patient organizations (Netherlands, Spain, and France). The mission of LAMA2 Europe is to accelerate the development of treatments for LAMA2-CMD and to support patients and their families by providing relevant information on international research activities related to LAMA2-CMD, and by collaborating and connecting patients and their families with clinicians, researchers, and members of the biotech industry.